Experimental bile duct cancer drug tested in tiny trial – already halted
NCT ID NCT06420349
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a new drug called NXP800 in 7 people with advanced bile duct cancer that had spread or stopped responding to treatment. The goal was to find a safe dose and see if the drug could shrink tumors by blocking a protein linked to cancer growth. However, the study was terminated early, so results are limited and it is not yet known if NXP800 works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NXP800
- What this could lead to
- If it works, this could point toward a new treatment option for advanced bile duct cancer that has stopped responding to standard therapies.
- What could go wrong
- This was a very early, small Phase 1 trial with only 7 patients, and it has already been terminated. It is unclear if NXP800 is safe or effective, and many early cancer drugs fail to show benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Action antibody boost chemo against bile duct cancer?
- Can a targeted pill outperform chemo for bile duct cancer?
- Can a pill target Hard-to-Treat bile duct cancers? a new drug puts FGFR2 mutations to the test
- New chemo combo targets Hard-to-Treat liver cancer
- New drug AB801 aims to boost chemo and immunotherapy in tough cancers
- New drug cocktail shows promise for tough bile duct cancer